{"title":"Anti-IgE therapy for asthma","authors":"Susan Berg","doi":"10.1016/S1088-0712(05)00043-9","DOIUrl":null,"url":null,"abstract":"<div><p><span>In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (</span><em>J Allergy Clin Immun</em> 2001;108:184-190, and <em>Eur Respi</em>r J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.</p></div>","PeriodicalId":100135,"journal":{"name":"Asthma Magazine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1088-0712(05)00043-9","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asthma Magazine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1088071205000439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (J Allergy Clin Immun 2001;108:184-190, and Eur Respir J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
